Integrated TCGA and GEO analysis showed that SMAD7 is an independent prognostic factor for lung adenocarcinoma.

The lack of effective markers leads to missed optimal treatment times, resulting in poorer prognosis In most cancers. SMAD family members are important cytokines in the transforming growth factor-beta (TGF-β) family. They jointly regulate the processes of cell growth, differentiation, and apoptosis. However, the expression of SMAD family genes in pan-cancers and their impact on prognosis have not been elucidated. Perl software and R software were used to perform expression analysis and survival curve analysis on the data collected by TCGA, GTEx and GEO, and the potential regulatory pathways were determined through GO enrichment and KEGG enrichment analysis. It was found that SMAD7 and SMAD9 expression decreased in Lung adenocarcinoma (LUAD), and their expression was positively correlated with survival time. Additionally, SMAD7 could be used as an independent prognostic factor for LUAD. In general, SMAD7 and SMAD9 can be used as prognostic markers of LUAD, further, SMAD7 is expected to become a therapeutic target for LUAD.